NydeggerUESturzeneggerM. Adverse effects of intravenous immunoglobulin therapy. Drug Saf. 1999;21:171-185.
2.
DalakasMC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.
3.
SekulEACuplerEJDalakasMC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-262.
4.
DalakasMC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(6, suppl 5):S2-S8.
5.
SakemBMatozanKNydeggerUEWeigelGGriesmacherARischL. Anti-red blood cell antibodies, free light chains, and antiphospholipid antibodies in intravenous immunoglobulin preparations. Isr Med Assoc J. 2013;15:617-621.
